Trial Profile
A Phase II Clinical Study of Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer Failed of Standard Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Raltitrexed (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results (As of November 2017; n=35) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 29 Sep 2017 Status changed from not yet recruiting to recruiting.
- 03 Dec 2015 New trial record